Case: 17-3030 Document: 24 Filed: 01/22/2018 Pages: 132 No. 17-3030 In the United States Court of Appeals for the Seventh Circuit ________________________________ WENDY B. DOLIN, Individually and as Independent Executor of the Estate of STEWART DOLIN, Deceased, Plaintiff-Appellee, v. GLAXOSMITHKLINE LLC, Formerly Known as SMITHKLINE BEECHAM CORPORATION, Defendant-Appellant. ________________________________ On Appeal from the United States District Court for the Northern District of Illinois No. 12-cv-6403 (Hon. William T. Hart) ________________________________ BRIEF OF APPELLANT ________________________________ Andrew T. Bayman Lisa S. Blatt Todd P. Davis Counsel of Record Heather M. Howard Elisabeth S. Theodore KING & SPALDING LLP William C. Perdue 1180 Peachtree Street, N.E. Stephen K. Wirth Atlanta, GA 30309 ARNOLD & PORTER KAYE SCHOLER LLP 601 Massachusetts Ave., N.W. Alan S. Gilbert Washington, DC 20001 DENTONS US LLP (202) 942-5000 232 S. Wacker Drive, Suite 5900 [email protected] Chicago, IL 60606 Counsel for GlaxoSmithKline LLC January 22, 2018 Case: 17-3030 Document: 24 Filed: 01/22/2018 Pages: 132 APPEARANCE & CIRCUIT RULE 26.1 DISCLOSURE STATEMENT Appellate Court No: 17-3030 Short Caption: Wendy Dolin v. GlaxoSmithKline LLC To enable the judges to determine whether recusal is necessary or appropriate, an attorney for a non-governmental party or amicus curiae, or a private attorney representing a government party, must furnish a disclosure statement providing the following information in compliance with Circuit Rule 26.1 and Fed. R. App. P. 26.1. The Court prefers that the disclosure statement be filed immediately following docketing; but, the disclosure statement must be filed within 21 days of docketing or upon the filing of a motion, response, petition, or answer in this court, whichever occurs first. Attorneys are required to file an amended statement to reflect any material changes in the required information. The text of the statement must also be included in front of the table of contents of the party's main brief. Counsel is required to complete the entire statement and to use N/A for any information that is not applicable if this form is used. [ ] PLEASE CHECK HERE IF ANY INFORMATION ON THIS FORM IS NEW OR REVISED AND INDICATE WHICH INFORMATION IS NEW OR REVISED. (1) The full name of every party that the attorney represents in the case (if the party is a corporation, you must provide the corporate disclosure information required by Fed. R. App. P 26.1 by completing item #3): GlaxoSmithKline LLC (2) The names of all law firms whose partners or associates have appeared for the party in the case (including proceedings in the district court or before an administrative agency) or are expected to appear for the party in this court: Arnold & Porter Kaye Scholer LLP; Dentons US LLP; King & Spalding LLP; Phillips Lytle LLP; Troutman Sanders LLP (3) If the party or amicus is a corporation: i) Identify all its parent corporations, if any; and GlaxoSmithKline LLC is an LLC whose sole member is GlaxoSmithKline Holdings (Americas) Inc. ii) list any publicly held company that owns 10% or more of the party's or amicus' stock: GlaxoSmithKline LLC is an indirect wholly-owned subsidiary of GlaxoSmithKline plc, a publicly traded company organized under the laws of England. Attorney's Signature: S/ Lisa S. Blatt Date: January 22, 2018 Attorney's Printed Name: Lisa S. Blatt Please indicate if you are Counsel of Record for the above listed parties pursuant to Circuit Rule 3(d). Yes X No Address: 601 Massachusetts Ave. NW Washington, DC 20001 Phone Number: (202) 942-5842 Fax Number: (202) 942-5999 Email: [email protected] rev. 01/15 GA American LegalNet, Inc. www.FormsWorkFlow.com Case: 17-3030 Document: 24 Filed: 01/22/2018 Pages: 132 Ý × Î Ý Ë × Ì Î Ë Ô Û î ê ò Ü × Í Ý Ô Ñ Í Ë Î Û Í Ì ß Ì Û Ó Û Ò Ì ß ° ° » ´´¿ ¬» Ý ± « ®¬ Ò ± æ ï éóíðíð Í ¸ ± ®¬ Ý ¿ ° ¬·± ² æ É»²¼§ ܱ´·² ªò Ù´¿¨±Í³·¬¸Õ´·²» ÔÔÝ Ì ± » ² ¿ ¾ ´» ¬¸ » ¶« ¼ ¹ » ­ ¬± ¼ » ¬» ®³ ·² » © ¸ » ¬¸ » ® ®» ½ « ­ ¿ ´ ·­ ² » ½ » ­ ­ ¿ ®§ ± ® ¿ ° ° ®± ° ®·¿ ¬» ô ¿ ² ¿ ¬¬± ®² » § º± ® ¿ ² ± ² ó¹ ± ª » ®² ³ » ² ¬¿ ´ ° ¿ ®¬§ ± ® ¿ ³ ·½ « ­ ½ « ®·¿ » ô ± ® ¿ ° ®·ª ¿ ¬» ¿ ¬¬± ®² » § ®» ° ®» ­ » ² ¬·² ¹ ¿ ¹ ± ª » ®² ³ » ² ¬ ° ¿ ®¬§ ô ³ « ­ ¬ º« ®² ·­ ¸ ¿ ¼ ·­ ½ ´± ­ « ®» ­ ¬¿ ¬» ³ » ² ¬ ° ®± ª ·¼ ·² ¹ ¬¸ » º± ´´± © ·² ¹ ·² º± ®³ ¿ ¬·± ² ·² ½ ± ³ ° ´·¿ ² ½ » © ·¬¸ Ý ·®½ « ·¬ Î « ´» î ê òï ¿ ² ¼ Ú » ¼ ò Î ò ß ° ° ò Ð ò î ê òï ò Ì ¸ » Ý ± « ®¬ ° ®» º» ®­ ¬¸ ¿ ¬ ¬¸ » ¼ ·­ ½ ´± ­ « ®» ­ ¬¿ ¬» ³ » ² ¬ ¾ » º·´» ¼ ·³ ³ » ¼ ·¿ ¬» ´§ º± ´´± © ·² ¹ ¼ ± ½ µ » ¬·² ¹ å ¾ « ¬ô ¬¸ » ¼ ·­ ½ ´± ­ « ®» ­ ¬¿ ¬» ³ » ² ¬ ³ « ­ ¬ ¾ » º·´» ¼ © ·¬¸ ·² î ï ¼ ¿ § ­ ± º ¼ ± ½ µ » ¬·² ¹ ± ® « ° ± ² ¬¸ » º·´·² ¹ ± º ¿ ³ ± ¬·± ² ô ®» ­ ° ± ² ­ » ô ° » ¬·¬·± ² ô ± ® ¿ ² ­ © » ® ·² ¬¸ ·­ ½ ± « ®¬ô © ¸ ·½ ¸ » ª » ® ± ½ ½ « ®­ º·®­ ¬ò ß ¬¬± ®² » § ­ ¿ ®» ®» ¯ « ·®» ¼ ¬± º·´» ¿ ² ¿ ³ » ² ¼ » ¼ ­ ¬¿ ¬» ³ » ² ¬ ¬± ®» º´» ½ ¬ ¿ ² § ³ ¿ ¬» ®·¿ ´ ½ ¸ ¿ ² ¹ » ­ ·² ¬¸ » ®» ¯ « ·®» ¼ ·² º± ®³ ¿ ¬·± ² ò Ì ¸ » ¬» ¨ ¬ ± º ¬¸ » ­ ¬¿ ¬» ³ » ² ¬ ³ « ­ ¬ ¿ ´­ ± ¾ » ·² ½ ´« ¼ » ¼ ·² º®± ² ¬ ± º ¬¸ » ¬¿ ¾ ´» ± º ½ ± ² ¬» ² ¬­ ± º ¬¸ » ° ¿ ®¬§ ù­ ³ ¿ ·² ¾ ®·» ºò Ý ± « ² ­ » ´ ·­ ® » ¯ « ·® » ¼ ¬± ½ ± ³ ° ´» ¬» ¬¸ » » ² ¬·® » ­ ¬¿ ¬» ³ » ² ¬ ¿ ² ¼ ¬± « ­ » Ò ñß º± ® ¿ ² § ·² º± ® ³ ¿ ¬·± ² ¬¸ ¿ ¬ ·­ ² ± ¬ ¿ ° ° ´·½ ¿ ¾ ´» ·º ¬¸ ·­ º± ® ³ ·­ « ­ » ¼ ò Å Ã Ð Ô Û ß Í Û Ý Ø Û Ý Õ Ø Û Î Û × Ú ß Ò Ç × Ò Ú Ñ Î Ó ß Ì × Ñ Ò Ñ Ò Ì Ø × Í Ú Ñ Î Ó × Í Ò Û É Ñ Î Î Û Ê × Í Û Ü ß Ò Ü × Ò Ü × Ý ß Ì Û É Ø × Ý Ø × Ò Ú Ñ Î Ó ß Ì × Ñ Ò × Í Ò Û É Ñ Î Î Û Ê × Í Û Ü ò øï ÷ Ì ¸ » º« ´´ ² ¿ ³ » ± º » ª » ®§ ° ¿ ®¬§ ¬¸ ¿ ¬ ¬¸ » ¿ ¬¬± ®² » § ®» ° ®» ­ » ² ¬­ ·² ¬¸ » ½ ¿ ­ » ø·º ¬¸ » ° ¿ ®¬§ ·­ ¿ ½ ± ®° ± ®¿ ¬·± ² ô § ± « ³ « ­ ¬ ° ®± ª ·¼ » ¬¸ » ½ ± ®° ± ®¿ ¬» ¼ ·­ ½ ´± ­ « ®» ·² º± ®³ ¿ ¬·± ² ®» ¯ « ·®» ¼ ¾ § Ú » ¼ ò Î ò ß ° ° ò Ð î ê òï ¾ § ½ ± ³ ° ´» ¬·² ¹ ·¬» ³ ý í ÷æ Ù´¿¨±Í³·¬¸Õ´·²» ÔÔÝ øî ÷ Ì ¸ » ² ¿ ³ » ­ ± º ¿ ´´ ´¿ © º·®³ ­ © ¸ ± ­ » ° ¿ ®¬² » ®­ ± ® ¿ ­ ­ ± ½ ·¿ ¬» ­ ¸ ¿ ª » ¿ ° ° » ¿ ®» ¼ º± ® ¬¸ » ° ¿ ®¬§ ·² ¬¸ » ½ ¿ ­ » ø·² ½ ´« ¼ ·² ¹ ° ®± ½ » » ¼ ·² ¹ ­ ·² ¬¸ » ¼ ·­ ¬®·½ ¬ ½ ± « ®¬ ± ® ¾ » º± ®» ¿ ² ¿ ¼ ³ ·² ·­ ¬®¿ ¬·ª » ¿ ¹ » ² ½ § ÷ ± ® ¿ ®» » ¨ ° » ½ ¬» ¼ ¬± ¿ ° ° » ¿ ® º± ® ¬¸ » ° ¿ ®¬§ ·² ¬¸ ·­ ½ ± « ®¬æ ß®²±´¼ ú ᮬ»® Õ¿§» ͽ¸±´»® ÔÔÐå Ü»²¬±²­ ËÍ ÔÔÐå Õ·²¹ ú Í°¿´¼·²¹ ÔÔÐå и·´´·°­ Ô§¬´» ÔÔÐå Ì®±«¬³¿² Í¿²¼»®­ ÔÔÐ øí ÷ ׺ ¬¸ » ° ¿ ®¬§ ± ® ¿ ³ ·½ « ­ ·­ ¿ ½ ± ®° ± ®¿ ¬·± ² æ ·÷ ×¼ » ² ¬·º§ ¿ ´´ ·¬­ ° ¿ ®» ² ¬ ½ ± ®° ± ®¿ ¬·± ² ­ ô ·º ¿ ² § å ¿ ² ¼ Ù´¿¨±Í³·¬¸Õ´·²» ÔÔÝ ·­ ¿² ÔÔÝ ©¸±­» ­±´» ³»³¾»® ·­ Ù´¿¨±Í³·¬¸Õ´·²» ر´¼·²¹­ øß³»®·½¿­÷ ײ½ò ··÷ ´·­ ¬ ¿ ² § ° « ¾ ´·½ ´§ ¸ » ´¼ ½ ± ³ ° ¿ ² § ¬¸ ¿ ¬ ± © ² ­ ï ð û ± ® ³ ± ®» ± º ¬¸ » ° ¿ ®¬§ ­ ± ® ¿ ³ ·½ « ­ ­ ¬± ½ µ æ Ù´¿¨±Í³·¬¸Õ´·²» ÔÔÝ ·­ ¿² ·²¼·®»½¬ ©¸±´´§ó±©²»¼ ­«¾­·¼·¿®§ ±º Ù´¿¨±Í³·¬¸Õ´·²» °´½ô ¿ °«¾´·½´§ ¬®¿¼»¼ company organized under the laws of England. ß ¬¬± ®² » § ù­ Í ·¹ ² ¿ ¬« ®» æ ­ñ ß´¿² Íò Ù·´¾»®¬ Ü ¿ ¬» æ Ö¿²«¿®§ îíô îðïè ß ¬¬± ®² » § ù­ Ð ®·² ¬» ¼ Ò ¿ ³ » æ ß´¿² Íò Ù·´¾»®¬ Ð ´» ¿ ­ » ·² ¼ ·½ ¿ ¬» ·º § ± « ¿ ®» ݱ«²­»´ ±º λ½±®¼ º± ® ¬¸ » ¿ ¾ ± ª » ´·­¬» ¼ ° ¿ ®¬·» ­ ° « ®­« ¿ ² ¬ ¬± Ý ·®½ « ·¬ Î « ´» í ø¼ ÷ò Ç » ­ Ò ± ß ¼ ¼ ®» ­ ­æ îíí ͱ«¬¸ É¿½µ»® Ü®·ª»ô Í«·¬» ëçðð ݸ·½¿¹±ô ×Ô êðêðê Ð ¸ ± ² » Ò « ³ ¾ » ®æ øíïî÷ èéêóéìïð Ú ¿ ¨ Ò « ³ ¾ » ®æ øíïî÷ èéêóéçíì Û óÓ ¿ ·´ ß ¼ ¼ ®» ­ ­æ ¿´¿²ò¹·´¾»®¬à¼»²¬±²­ò½±³ ®» ª ò ð ï ñ Case: 17-3030 Document: 24 Filed: 01/22/2018 Pages: 132 APPEARANCE CIRCUIT RULE 26.DISCLOSURE STATEMENT Appellate Court No: 17-3030 Short Caption: Wendy Dolin v. GlaxoSmithKline LLC To enable the judges to determine whether recusal is necessary or appropriate, an attorney for a non-governmental party or amicus curiae, or a private attorney representing a government party, must furnish a disclosure statement providing the following information in compliance with Circuit Rule 26.1 and Fed. R. App. P. 26.1. The Court prefers that the disclosure statement be filed immediately following docketing; but, the disclosure statement must be filed within 21 days of docketing or upon the filing of a motion, response, petition, or answer in this court, whichever occurs first. Attorneys are required to file an amended statement to reflect any material changes in the required information. The text of the statement must also be included in front of the table of contents of the party's main brief. Counsel is required to complete the entire statement and to use N/A for any information that is not applicable if this form is used. [ ] PLEASE CHECK HERE IF ANY INFORMATION ON THIS FORM IS NEW OR REVISED AND INDICATE WHICH INFORMATION IS NEW OR REVISED. (1) The full name of every party that the attorney represents in the case (if the party is a corporation, you must provide the corporate disclosure information required by Fed. R. App. P 26.1 by completing item #3): GlaxoSmithKline LLC (2) The names of all law firms whose partners or associates have appeared for the party in the case (including proceedings in the district court or before an administrative agency) or are expected to appear for the party in this court: King & Spalding, LLP; Dentons US LLP; Arnold & Porter Kaye Scholer LLP; Phillips Lytle LLP. (3) If the party or amicus is a corporation: i) Identify all its parent corporations, if any; and GlaxoSmithKline LLC is a LLC whose sole member is GlaxoSmithKline Holdings (Americas) Inc. ii) list any publicly held company that owns 10% or more of the party’s or amicus’ stock: GlaxoSmithKline LLC is an indirect wholly-owned subsidiary of GlaxoSmithKline PLC, a publicly traded* Attorney's Signature: s/ Andrew T. Bayman Date: November 15, 2017 Attorney's Printed Name: Andrew T. Bayman